Exuma Biotech is a clinical-stage biotechnology company discovering and developing Chimeric Antigen Receptor (CAR)-T cell products for solid tumors. They develop new tools for the patient’s immune system to fight various solid tumor malignancies, such as renal cell carcinoma, soft tissue sarcoma, gastric cancer, and others. It was founded in 2015 and headquartered in Grand Cayman, Midland.